10835 Road to the Cure, Suite 140
About Erasca, Inc.
Erasca, Inc. is a San Diego based biotechnology company focused on discovering and developing precision medicines for the benefit of patients with cancer. Our programs, currently focused on innovative discovery research, take novel approaches to shutting down certain oncogene drivers of solid tumor malignancies. The name “Erasca” has an important embedded meaning: It is a contraction of our audacious hope to “erase cancer” that drives our mission and everything that we do on behalf of patients with cancer.
3 articles with Erasca, Inc.
Erasca Announces Key Leadership Team Appointments and Recruits World-Class Research and Development Advisory Board
Erasca, a company dedicated to advancing exceptional scientific approaches to erase cancer, today announced the promotion of Gary Yeung, CFA, to chief operating and financial officer, as well as the appointment of David Chacko, M.D., to chief business officer. Les Brail, Ph.D., has been appointed vice president of clinical development, and Karen Gilmore, CPA, has been appointed vice president of finance.
Proceeds of financing will fuel corporate development efforts and further buildout of artificial intelligence platform to accelerate drug discovery in bold mission to erase cancer
Days before Christmas, three new companies decided to strip away the wrapping paper and unveil themselves to the world. Each of the companies launched with millions of dollars raised through a Series A financing round.